Contact lenses as a means to deliver pharmaceuticals to the eye have seen a significant increase in research interest in the past few years. This review will detail the in vitro experiments which have investigated use of these contact lenses in the context of the desired pharmacological treatment goals in the management of infectious, inflammatory, allergic and glaucomatous diseases of the eye. The techniques researchers have employed to modify and tailor drug release rates from these materials, including the use of vitamin E diffusion barriers, modified ionicity, molecular imprinting and incorporation of drug reservoirs, will be discussed, as well as their impact on drug release kinetics. Finally, the demonstration of the feasibility of these materials when applied in vivo in animal models as well as in humans with and without disease will be presented and their results discussed relating to their implications for the future of the field.
The use of soft contact lenses as a means to deliver drugs to the eye is not a novel concept, having been included in the original hydrogel patent by Wichterle and Lim in the 1960s. 1 With a greater understanding in the fields of biomaterials and bioengineering, there has been an increase in contact lens drug delivery research since the early 2000s, 2 with developments in sustained drug delivery in the fields of cardiac, oncology and orthopaedic medicine providing some encouragement on investigations into this type of technology. [3] [4] [5] The potential interest in sustained drug delivery to the eye via a contact lens system is understandable. Contact lenses are arguably the most successful biomaterial in commercial use, with a long history of successful commercialisation, biocompatibility and acceptance by patients and prescribing practitioners. 6, 7 The pharmacological goals of topical ocular therapy are also clear, with achievement of therapeutic concentrations at the site of interest without periods of under-or over-treatment being combined with an acceptable means of delivery. 8 Eye-drops and ointments are the most common topical means to treat the eye, and are able to achieve these pharmacological goals even in the face of significant practical and pharmacological limitations. Eye-drops are limited by their bioavailability, the amount of active ingredient within the formulation which reaches the intended site of action, due to absorption barriers of the cornea, non-productive absorption by the conjunctiva and the diluting and flushing action of tears. 8 Productive corneal absorption of the active ingredient in an eye-drop is opposed by the epithelial, stromal and endothelial corneal structures, all of which present different soluble barriers which must be overcome by the drug of interest if intraocular structures are to be targeted. 8 In contrast, the conjunctiva readily absorbs substances in comparison to the cornea due to its increased permeability and surface area, but this absorption is considered nonproductive due to efficient venous and lymphatic drainage away from the eye. 8 Increased tear production and tear turnover are also induced due to drop instillation itself, decreasing the ocular residence time, and thus opportunity for drug absorption, to only a few minutes. 9 Drug components drained from the eye via the lacrimal drainage system are ultimately absorbed systemically where they carry the risk of inducing undesirable systemic allergic or pharmacological actions. 9 Eye-drops as a drug delivery system are capable of overcoming some of these pharmacological limitations through frequent dosing and proper drop instillation techniques, although for many patients this requires significant effort and intention on their part which ultimately decreases compliance and treatment success rates.
Compliance with ocular medication continues to present a challenge to the industry, especially in the management of chronic conditions such as glaucoma, where compliance is generally considered to be poor. It is estimated that only up to 50 per cent of glaucoma patients managed with eye-drops are fully compliant over time, and compliance generally decreases with increasing frequency of drop instillation and number of medications or bottles of drops used. 10 Other options for topical ocular therapy, ointments and gel formulations, with their increased viscosity, ease the burden of compliance through less frequent dosing; however, their detrimental impact on vision generally hampers their overall usability. 8 As an alternative, contact lens-based drug delivery systems can specifically address some of the pharmacological limitations of topical ophthalmic therapy.
Compliance with medication can potentially be increased through two avenues. Concurrent correction of refractive error, if present, would provide a significant incentive to utilise the device and thus simultaneously receive drug treatment. If properly engineered, the appropriate dosage could also be delivered throughout the intended course of contact lens wear, eliminating the need for frequent dosing or lens changes. Modification and control of dosage delivered over time, or the drug release kinetics, has been the focus of the field in recent years. 2 
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characteristics from contact lenses or novel contact lens-like materials, all with different manufacturing methods and impact on material properties which are discussed below and summarised in Figure 1 . In this review, the methods utilised by researchers to investigate and design contact lens drug delivery systems are detailed, and followed by discussion of applicability of these materials in the delivery of agents to manage ocular infection, inflammation, allergy and glaucoma.
METHODS OF INVESTIGATION AND MODIFICATION OF DRUG-DELIVERING CONTACT LENSES Drug delivery and unmodified commercial contact lenses
The use of unmodified, commercially available contact lenses provides insight into the effect of simply introducing a commercially available lens to the ocular surface during topical treatment. Commercially available lenses have the advantage when used for investigation of drug release properties of being readily available and manufactured on a large scale, ensuring a consistent and reproducible product. Multiple investigations of various commercially available lenses and different drugs have allowed for conclusions to be made into the factors which influence drug uptake and release in vitro such as nature of the material backbone, the overall lens water content and surface charge. [12] [13] [14] [15] [16] [17] [18] Unsurprisingly, a recurring theme with these materials which were never engineered to deliver pharmaceuticals is that while they may be able to uptake and release substantial amounts of pharmaceuticals from eye-drop solutions, the release kinetics from them tend to be rapid and uncontrolled and thus unsuitable for long-term drug delivery. [16] [17] [18] Testing of drug-soaked commercial lenses have also been done in humans, generally in short-term, pre-surgical contexts to evaluate the effectiveness of lenses in comparison to eye-drops in achieving pre-surgical prophylactic or therapeutic levels. 19 Drug delivery from modified commercial contact lenses: vitamin E diffusion barriers Given these in vitro pharmacokinetic limitations of unmodified, commercial contact lenses as a means to deliver ocular pharmaceuticals, researchers have attempted to modify these materials to add on desired drug pharmacokinetic properties principally to slow drug release rates. The use of vitamin E, a hydrophobic liquid, has been extensively investigated as a means to modify commercial contact lenses. If drug release from a contact lens is considered to be a diffusion-controlled process, the release rate is affected by both the diffusivity, or the ability of a particular drug to diffuse through a material, and the path length through which the drug must pass through before being released. 20 The diffusivity is generally a constant property of a particular lens-drug combination, and so to modify drug release the path length can be modified either through an increase in thickness or by some other means. 20 As vitamin E is hydrophobic, has low water solubility and is biocompatible with the ocular surface, deposition of a layer of vitamin E onto the surface of commercial contact lenses can substantially increase the path length through which drugs or other molecules would be required to travel to diffuse out from a commercial contact lens core. 20 Both silicone and non-silicone hydrogel commercially available lenses have been modified using this approach, leading to substantial increases in drug release time from a few hours unmodified to a few weeks with appropriate coating thicknesses and drug-lens combinations. [20] [21] [22] [23] [24] [25] The feasibility of this technology is strengthened by both the biocompatibility and relatively acceptable optical characteristics of the deposited vitamin E layer, which additionally also provides some degree of ultraviolet light protection. 20 Deposition of the barrier involves soaking of commercial lenses in a vitamin E and ethanol solution, the composition of which can vary depending on the desired amount of vitamin E to be deposited. The concern with modification of commercial lenses for drug delivery is the effects of the deposited barrier on lens size, oxygen diffusion and ion permeability, all of which have . Strategies investigated to modify and extend drug release times from existing contact lenses or novel contact lens materials. Drug release can be modified through molecular imprinting, where areas within a polymer are generated at a molecular level to specifically interact non-covalently to molecules of interest and thus slow diffusion from the material (A), through incorporation of a drug reservoir, typically consisting of poly lactic-co-glycolic acid (PLGA) to serve as a source of the molecule of interest (B), by incorporation of a biocompatible barrier to diffusion such as vitamin E on the lens surface (C) or by modifying the ionic characteristics of the lens through incorporation of anionic or cationic molecules during material synthesis (D been shown to be affected negatively to some degree, depending on the amount of vitamin E deposited. 20 There has also been a lack of studies investigating the longevity of the vitamin E barriers to typical contact lens use and handling, and it is unknown whether the barrier function would be able to persist through a typical contact lens cleaning regimen or if they would be intended to be used once before discarding.
Drug delivery from novel materials: molecular imprinting
Molecular imprinting is one of the most widely investigated methods in which novel contact lens materials have been created specifically for the sustained and increased release of ocular pharmaceuticals. 26, 27 Molecular imprinting is a polymerisation technology which generates areas of complementary shape and functional groups to a molecule of interest within the final polymer. 28 This is accomplished through inclusion of the molecule of interest (the template) within the pre-polymerisation mixture along with functional monomers, molecules designed to interact noncovalently with the template. 29 After polymerisation, complementary areas to the template on a molecular scale are created which significantly increase the affinity of the polymer to the template of interest and thus slow down diffusion from the generated materials. 27 Through numerous experiments, some of the crucial features of this process to successfully increase drug release times have been elucidated, with the selection and relative ratio of the functional monomer to the template and concentration of the polymer cross-linker in the polymerisation mixture proving to be most critical to success. 30 The technique has also continued to evolve by taking cues through study of the characteristics of the drug receptors, with some groups selecting the number, type and relative ratios of functional monomers to best mimic the receptor with which the drug will ultimately interact within the body. 31 It is crucial to understand that the interactions of the template molecule and interacting molecules in the final polymer are all non-covalent, consisting of Van der Waals forces, ionic attractions and hydrogen bonding, so there are no chemical bonds which need to be broken to allow for drug release. The strength of the molecular imprinting process is in its versatility. As long as appropriate functional monomers can be identified to be used with the target templates, this technique remains viable, and the expectation will be that as more drug receptors are identified, suitable combinations of functional monomers and drugs can also be identified to be exploited using this technique. 31 As the drug typically acts as a template molecule within the pre-polymerisation mixture, materials manufactured using this technique typically require a wash step to remove used template molecules prior to reloading with known amounts of drug. There also appears to be some material limitations to the effectiveness of the imprinting process. If the concentration of the cross-linker used to generate the polymer is too low, there will be insufficient structural rigidity to allow for the target molecules to be efficiently captured and held by the imprinted material. 26 There also exists an upper limit to the proportion of the polymer which can be imprinted and have it continue to function as a contact lens, as when the drug is released into solution there may be detrimental structural effects on the physical contact lens characteristics.
Drug delivery from novel materials: modified material charge
Many ophthalmic pharmaceuticals have ionic charges which can be exploited to increase loading and release from drug release systems. The Food and Drug Administration (FDA) in the USA classifies contact lens materials in part by the presence or absence of a surface charge. This was in part to guide practitioners as to the predicted tear deposition and preservative uptake characteristics from these materials when used in different patients and with different cleaning solutions. 32, 33 The surface charge of these materials has also been shown to have an effect on the uptake and release of charged pharmaceutical drugs, with charged materials in FDA category IV and drugs such as ciprofloxacin hydrochloride, sodium cromoglycate and chlorpheniramine maleate demonstrating an increased loading and release compared to other materials. 34, 35 To further enhance this, novel materials have incorporated increasing amounts of anionic molecules such as methyl acrylic acid (MAA) and 2-methacryloxyethyl phosphate into the polymer to change the overall charge and attract complementary charged drug molecules. 36, 37 A concern with the change in surface charge of these molecules is the increased propensity for deposition of tear film constituents such as proteins, especially if the lenses are to be worn for long periods between cleaning and conditioning. 36 The method also does not lend itself to application with drugs which are not easily charged, such as many of the antiinflammatory corticosteroids or the immunomodulatory agent cyclosporine A, which tend to be larger, hydrophobic molecules.
Drug delivery from novel materials: PLGA drug reservoirs
Poly lactic-co-glycolic acid, or PLGA, is one of the most extensively studied materials for drug delivery applications in the body due to its biocompatibility, bioerodability and FDA approval for use in humans. 38 It has been studied not only in ocular applications, but also as a means for tissue scaffolds and drug delivery implants in the rest of the body. 38 The material has a high strength and release characteristics that can be tailored through the relative composition of the lactide to glycolide in the final material. 38 Incorporation of several ophthalmic drugs, including econoazole, latanoprost, fluorescein and ciprofloxacin have been individually made with PLGA, after which they can be encapsulated into two sides of a hydrogel material together to create a contact lens drug delivery device. [39] [40] [41] By disassociating desired drug release characteristics from being necessarily borne by the contact lens material and rather taken up by a substance engineered for this purpose, substantial tailoring of the amount and rate of drug release can be achieved with this technique, with in vitro and in vivo reports suggesting that relevant release rates can be sustained for a month or more. 41 The addition of the PLGA drug releasing component unfortunately significantly detracts from the application of these devices as contact lenses, as PLGA, even in very thin layers, is at best translucent and does not transmit visible light as effectively as the hydrogel material itself. [39] [40] [41] Incorporation of the PLGA also has a detrimental effect increasing the overall thickness of the lens.
Other methods of modifying drug release from contact lenses deposited layers of liposomes or nanoparticles, with the drug of interest encapsulated in these molecules and deposited in layers onto the contact lens surface. 42, 43 The drug is then forced to be released from the liposomes or nanoparticles through interaction with the tear film, with each layer serving as an additional reservoir. Release of pharmaceuticals from deeper layers must also diffuse through previous layers prior to being released on the surface. Thus release from these materials typically demonstrate several phases of different release kinetics, with an initial fast burst release phase from drug released in the outer layers followed by a slower, sustained phase from drug diffusion from the inner layers. 
Management of ocular infection with drug-delivering contact lenses
There is a strong association between infections on the cornea and the use of contact lenses, and this incidence increases with extended wear of these devices. 44 This simple fact potentially limits the marketplace for antibiotic-releasing contact lenses due to negative perceptions of the associations of contact lenses and infections by healthcare practitioners. Regardless, delivery of antibacterial, anti-fungal, anti-viral and preservative agents have all been investigated to some degree from unmodified, commercially available and specifically engineered drug delivery materials both in vitro and in vivo. 30, 34, 37, 39, 40, 43, [45] [46] [47] [48] [49] The acute therapeutic and pharmaceutical management goals with infections can be different compared to other forms of ocular pharmaceutical management, as it is often the case that a high therapeutic concentration is sought in the target tissues as rapidly as possible, and that concentration maintained within the tissue over time through repeat administrations. 8 In practice, implementation of these pharmaceutical goals leads to initial frequent dosing to quickly saturate the ocular tissues and reach minimum inhibitory concentrations. 50 Once achieved, dosage frequencies are decreased dramatically to a dose every few hours to maintain high concentration levels in the tissues until the infection is cleared, at which point the treatment can be immediately discontinued. Immediate cessation of treatment is considered essential so there are no periods of sub-therapeutic treatment which has the potential to promote the development of resistance. An ideal antibiotic-releasing contact lens would thus be tasked with two different drug release requirements: an initial rapid and large drug release to reach minimum inhibitory concentration levels, followed by a sustained delivery for an extended period of time to maintain concentrations within the tissues. If only examined in vitro, the ideal release kinetics would thus appear to be a very rapid rise to a therapeutic concentration, followed by a slower drug release rate to maintain drug concentration in face of biological excretion from the tissue. A summary of selected studies utilising contact lenses to deliver ophthalmic antimicrobial agents is presented in Table 1 .
Investigations of antimicrobial release from commercially available contact lenses have in general all reported similar trends when investigated in vitro under static solution release conditions. In static solution release experiments, drug-loaded lenses are placed into a large releasing solution and drug concentrations monitored over time generally without any change or replenishment of the release solution. In these conditions, commercial lenses are capable of releasing large amounts of drugs but do so at a comparably rapid and uncontrolled rate. Ciprofloxacin release from commercially available conventional and silicone hydrogel materials is illustrative of the typical results seen with unmodified commercial lenses. 17, 34, 48 Ciprofloxacin is a second-generation fluoroquinolone that exists as a zwitterion at physiological pH, a molecule with both negative and positively charged functional groups, which hamper its aqueous solubility. For topical ophthalmic preparations the pH is thus modified to 4.0 to allow for drug solubility as this renders the molecule to have an overall positive charge. The greatest amount of ciprofloxacin release from commercial lenses was reported to be from etafilcon A lenses, presumably due to ionic/charged interaction occurring between the charged drug molecule and the lens surface. 34 The lenses were reported to release 0.48 AE 0.003 mg/lens of ciprofloxacin for a maximum of 25 minutes when observed in this type of system. Natamycin, an antifungal agent, has also been similarly investigated for release from commercial contact lenses with similar results. 47 Antimicrobial release from commercial contact lenses has been particularly useful to highlight effects of different release conditions on drug release rates. Under models of physiological tear flow through a contact lenses over time, where a small volume of fluid is passed through a contact lens by a pump system before being collected and analysed, the kinetics of release are remarkably different from static release conditions even if the overall release volume is the same. Flow of 4.8 mL of phosphate-buffered saline (PBS) through the contact lens over a period of 24 hours in a microfluidic system results in apparently much more favourable release kinetics as the drug is released at a more consistent rate over time in comparison to the same lenses placed directly into a large volume of 4.8 mL of PBS. 48 Several researchers have investigated utilising liposomal, molecular imprinting, vitamin E diffusion barriers and ionicity modifications to extend or modify antimicrobial drug release. 25, 30, 37, 42, 43, 45, 46 Molecular imprinting of model poly-hydroxylethyl methacylate (pHEMA) lenses utilising acrylic acid as a functional monomer demonstrated a marked improvement in the in vitro release of norfloxacin, a fluoroquinolone antibacterial, with a reported 4:1 functional monomer-to-template ratio providing the greatest benefit to extending release. 30 Similar methods and acrylic acid as a functional monomer were also utilised to generate materials for another fluoroquinolone, ciprofloxacin, with reports of significant drug release times extending for upward of two weeks. 45 The application of several layers of the fluoroquinolone levofloxacin-laden liposomes on to the surface of commercial contact lenses has also been reported to have a marked effect on the drug release characteristics which approach the ideal drug release kinetics. 42 The authors interpret two phases of drug release from lenses with five or 10 liposomal layers deposited onto the lens surface. There was an initial fast release phase where a large proportion of the drug is released into solution followed by a second phase where levofloxacin continues to be released for up to 120 hours albeit at a significantly slower rate. 42 The rapid release is thought to be from the outermost liposomal layers in contact with the releasing solution, 25 It has also been used as a means to slow down the release of fluconazole, an anti-fungal agent. 20 It was found that increasing the amount of vitamin E loaded on to the surface of the contact lens significantly increases the release time of similar amounts of the anti-fungal drug, with extension of release observed beyond 200 hours for lenses with the largest amount of vitamin E deposited. However, it was observed that the total amount of drug released over time did not increase with increased vitamin E usage; this release was simply spread over a longer period of time. 20 The use of nanoparticles encapsulating natamycin on pHEMA-(Tris[trimethylsiloxy]silyl)-propyl methacrylate (pHEMA-TRIS), a model silicone hydrogel material, has also been explored. Encapsulation of natamycin into nanoparticles allows for the hydrophobicity of the natamycin to be masked and thus increase observed solubility. 43 As the nanoparticles are released from the contact lens, the drug slowly becomes dissolved from the nanoparticles into solution. Incorporation of these nanoparticles increases the observed drug release time to 12 hours compared to one hour with nonencapsulated natamycin, although it is worth noting that this effect was considered to be due mainly to drug release from the nanoparticles themselves, which would have been released from the contact lenses rapidly and potentially lost to the tear drainage prior to natamycin release if used in vivo. 43 Econazole, another antifungal agent, has also been incorporated into a curved PLGA film before being sealed between two layers of pHEMA. 40 The resultant device was demonstrated to have a curved shape and typical diameter of a contact lens, although the drug-laden film was still white and opaque to the transmission of visible light. 40 When tested in vitro, fungicidal levels of econazole were released into solution for upward of three weeks. Interestingly, as the PLGA film dissolved and econazole released, the transparency of the film increased to a semi-transparent state which could prove helpful in identifying the amount of drug remaining in the delivery system, although this was still not as transparent as the contact lens material itself. 40 Similar experiments performed using ciprofloxacin and PLGA demonstrated an almost concentration-independent or zero order release rate into solution in vitro over the course of one month of observation, where a large proportion (77 per cent) of the initial loaded drug remained to still be released albeit from an overall thick film and lens combination. 39 In vivo testing of antimicrobial-releasing contact lenses can provide an ultimate assessment of the effectivity and viability of this technology due to the multitude of potential microbiological techniques and models available in this field. Animal models of keratitis and endopthalmitis can be utilised to assess the ability of the released antibiotic dose over time to combat or prevent infection. For example, a molecular imprinted contact lens formed from pHEMA-TRIS for the release of ciprofloxacin was directly compared with topical eye-drop instillation in a rabbit model of bacterial keratitis. 46 Keratitis was induced through a corneal abrasion and introduction of a ciprofloxacin-susceptible strain of Pseudomonas aeruginosa isolated from a human microbial keratitis case. After development of signs and symptoms of keratitis, rabbits were treated with topical eye-drops and unmodified, drug-loaded control lenses or molecular imprinted lenses designed for prolonged ciprofloxacin release. The amount of bacteria recovered from extracted corneas 24 hours after bacteria inoculation was used as an outcome measure, with imprinted lenses significantly reducing the number of recovered bacteria to statistically similar levels seen with hourly antibiotic eye-drop instillation. 46 Crucially, there was some evidence of an increase in bioavailability to the cornea via contact lenses in comparison to eye-drops as the tested lenses were loaded with antibiotic concentrations 100 times less than the topical eye-drops utilised. 46 Modified anionic lenses have also been designed for the release of antibiotics including the newer generation fluoroquinolone moxifloxacin and gatifloxacin. Placement of these anionic materials loaded with antibiotics on to the surface of Japanese albino rabbits led to greater antibiotic concentrations observed in the cornea, aqueous humour and crystalline lenses compared to eyedrops. 37 When challenged with a Staphylococcus aureus model of endopthalmitis, where an inoculum of bacteria was directly injected into the anterior chamber, only gatifloxacin delivered from anionic modified lens materials were successful in preventing the development of endopthalmitis in comparison to prophylactic treatment with topical eye-drops. 37 In vivo testing of antibiotic-releasing contact lenses has not been limited to only animal models. Many studies have investigated the use of antibiotic-releasing contact lenses in humans for prophylaxis, often in the context of comparative treatment regimens prior to ocular surgery for conditions such as cataracts. 19, 51, 52 For some drugloaded lenses, inhibitory concentrations are still found in the tear film after several days of continuous wear, as evidenced by a study involving gentamicin, an aminoglycoside antibacterial, and commercially available pHEMA lens. 51 In comparison to typical preoperative antibiotic dosing regimens, which may consist of nine to 10 drops of antibiotics two hours prior to surgery, use of a commercially available contact lens soaked in gentamicin, ofloxacin and ciprofloxacin on the ocular surface prior to the procedure, all have been demonstrated to lead to greater aqueous humour concentrations when sampled during the surgical procedure itself. Relevant antibiotic concentrations have also been demonstrated to persist within the aqueous humour after the procedure for up to six hours. 19 
Management of ocular inflammation with drug-delivering contact lenses
Management of ocular inflammation requires balancing of suppression of the immune response to prevent collateral damage, while also allowing for the body to process and deal with the injurious stimulus which precipitated the condition and initiate healing. 8 The mainstay of management of acute, moderate to severe inflammation is through the use of corticosteroids which have powerful antiinflammatory effects. 8 However, their use is complicated through concerns of potentially blinding side-effects including uncontrolled ocular hypertension which can lead to glaucoma, development of cataracts with prolonged use in certain individuals, and secondary infection due to suppression of the immune system. 8 Use of corticosteroids is also further complicated by the need to taper the drug dosage over time after inflammation has been controlled, to allow for the body to return to normal homeostasis and prevent rebound inflammation. In the ideal scenario for acute management of inflammation with corticosteroids, the therapeutic concentrations found within the eye would quickly rise to therapeutic levels, and these therapeutic levels would be maintained over time. Once inflammation has subsided, the requirements would be for the drug concentrations to be reduced slowly at a controlled rate. Thus, if observed in vitro over time, the ideal drug release from corticosteroid-releasing drug delivery systems would be an initial steep slope to reach therapeutic concentrations, followed by a second phase with a significantly flatter slope to maintain drug concentrations against drug turnover and elimination. In contrast to treatment of infection, the need for a tapering period would necessitate that the drug release would ideally see a third phase with a release rate which is less than that of the drug elimination rate so that the corticosteroid concentration could decrease at a controlled rate slowly over time. The turnover and removal of the corticosteroid would be at a higher rate than the drug release from the system, but there should still be some drug being released at a diminishing rate until treatment cessation.
Whether it is necessary for these different release rates to be engineered into a single device will depend on the end stage application of a particular device, and it is envisaged that several devices with different drug release rates are likely to be necessary. Selected studies investigating the release of anti-inflammatory agents from contact lenses and contact lens materials are summarised in Table 2 .
Release of dexamethasone sodium phosphate, a corticosteroid used in the management of ocular inflammation, has been observed from commercial contact lenses in vitro. Similar to the drug release behaviour with antibiotic agents, release is generally uncontrolled and occurs in a rapid burst release in vitro for periods of less than one hour. 34 It would appear that a greater amount of dexamethasone sodium phosphate is released from hydrogel versus silicone hydrogel materials. 34 Modification of commercial contact lenses with vitamin E has been demonstrated to improve the release duration of dexamethasone to upwards of 16 days. 21 Chitosan nanoparticles have also been investigated as a means to control release of dexamethasone sodium phosphate from contact lens materials. 56 Chitosan is a polysaccharide derived from chitin, a component of the outer shells of crustaceans, which has been extensively investigated for its drug delivery applications. 57 Highly negatively charged dexamethasone sodium phosphate paired with positively charged chitosan nanoparticles have been incorporated during pHEMA synthesis. The incorporation of the nanoparticles into the polymer matrix serves as an additional barrier to dexamethasone release, leading to 50 per cent of the total amount of the drug released from these systems (43 μg) occurring over 10 days in comparison to only three days from the nanoparticles alone. These materials continue to release dexamethasone phosphate at a decreasing rate into solution until an observed plateau after 22 days, which could be useful pharmacokinetically for management and tapering protocols for corticosteroids. The authors report that the incorporation of the nanoparticles and dexamethasone did not appreciably impact the light transmittance of the generated materials, with 95-98 per cent of the wavelengths between 400 and 800 nm continuing to be transmitted compared to unmodified pHEMA. 56 Molecular imprinting has been investigated as a technique for the sustained release of prednisolone acetate, another potent corticosteroid used in the management of moderate to severe ocular inflammation. 58 MAA in various ratios has been utilised to act as a functional monomer to interact with key functional groups of prednisolone in the final pHEMA material. Inclusion of MAA leads to an increase in the uptake of prednisolone into the materials, and materials created with a molar ratio of MAA to prednisolone acetate of four to one and a cross-linker concentration of 200 mmol/L demonstrating in vitro release into solution for 48 hours. 58 Nonsteroidal anti-inflammatory drugs (NSAIDs) are utilised in eye care for the prevention of intraoperative miosis and the management of pain, inflammation and allergy. 8 They are also utilised post-cataract surgery for the management or prevention of cystoid macular oedema. 8 In comparison to the corticosteroids, there is less concern surrounding rebound inflammation if these agents are discontinued suddenly as their pharmacodynamics effects are only on cyclo-oxygenase enzymes which are downstream in the inflammatory process. 8 Natural applications of NSAID-releasing contact lenses would be for corneal pain management, as NSAIDs are already routinely being prescribed in conjunction with bandage contact lenses in cases of postphotorefractive keratectomy, a laser vision correction procedure, and in the management of corneal abrasions. Studies with NSAIDs have observed the uptake and release characteristics from commercial contact lenses, where lenses with the greater water content, pHEMA material and ionic charge, showing the greatest release into solution under infinite sink conditions over 50 hours. 59 Model pHEMA lenses cross-linked with polyethylene glycol dimethacrylate have been synthesised and investigated for diclofenac sodium, an NSAID, released using a molecular imprinting strategy with diethylaminoethyl methacrylate serving as the functional monomer. 60 Loading of the drug was demonstrated to be due to ionic bonding between the drug and polymer network. Reports of release studies of these materials are notable for different conditions utilised. In addition to the traditional infinite sink method, which utilises large volumes, the authors in this study sought to simulate in vivo tear flow through the materials with a microfluidic device which could pass artificial tear fluid through at a 'physiological' tear flow rate of 3 μL/min. Comparison of the data generated under the two different conditions further illustrates the effects of in vitro release conditions on the observed drug release behaviour as they did for small volume flow rates from commercial contact lenses and antibiotics as previously discussed. 48 The molecular imprinting effect is demonstrable under infinite sink conditions, with approximately 800 μg of diclofenac released over the course of 72 hours compared to 400 μg released over nine hours for the unmodified control. Under physiological flow rates, the release rates were shown to be close to zero order over the course of 48 hours, with release rates ranging from 6.75-11.72 μg/hour depending on the degree of imprinting, demonstrating the possibility for some degree of tailoring of drug release rate to the degree of imprinting. 60 Cyclosporine A is an immunomodulatory agent utilised on the eye for the chronic management of dry eye, inflammation and allergy Contact lenses for ophthalmic drug delivery Hui and is also used to facilitate organ transplantation elsewhere in the body. 8 The compound has relatively poor aqueous solubility and for ophthalmic use it is strictly formulated as an emulsion. 61 Incorporation of the drug into a traditionally hydrophilic hydrogel would thus present some difficulties with regard to drug solubility in the hydrophilic components of the lens as well as potential impact on light transmission. To combat this, researchers have reported on the creation of microemulsions or surfactant-laden pHEMA hydrogels, where inclusion of these additional substances allowed for an increased solubility of the drug within the hydrogel and subsequent slow release into the aqueous media. Incorporation of these substances into hydrogel synthesis increased the drug release into solution to approximately 20 days compared to less than seven days for base hydrogel material. 62 Importantly, incorporation of cyclosporine A within these substances further solubilises the drug and allows for satisfactory light transmittance characteristics. 63 Vitamin E diffusion barriers have also been investigated for their ability to slow the release of cyclosporine A. 64 Due to the presence of hydrophobic monomers, cyclosporine-loaded commercial silicone hydrogel materials are already readily able to demonstrate extended cyclosporine A release periods of 15 days or more into aqueous solutions such as PBS without modification. This is likely to be due to observed solubility effects of the drug in an aqueous medium. Incorporation of a vitamin E diffusion barrier significantly increases this release time into solution of a month or more. 64 There has been limited in vivo testing of anti-inflammatory release from contact lenses. 11 In one example within the literature, patients undergoing cataract extraction were pre-treated with the dexamethasone either through a drug-soaked Sauflon 70 contact lens or through subconjunctival injection. 65 The concentration of dexamethasone persisted in the aqueous humour for at least 12 hours, with no drug being detectable after 24 hours. However, in comparison to the subconjunctival injection, the use of a contact lens led to a lower peak concentration and did not persist within the aqueous humour for a long time. 65 
Management of ocular allergy with drug-delivering contact lenses
The pharmacological management of ocular allergy involves a stepped approach through various classes of medications depending on the severity of presentation and response to therapy. 8 Preventative management of allergy with mast cell stabilisers, to decrease the frequency of degranulation and histamine release, requires preemptive treatment prior to exposure with allergens, while antihistamines can be utilised to prevent further action of already released histamine on ocular tissues. Combination antihistamine-mast cell stabiliser drugs are available and commonly used to exert both of these pharmacodynamic actions to some degree. 8 From a pharmacokinetic perspective, the ideal in vivo concentration profile of the drug is one that reaches and maintains effective concentrations in the targeted site of action for a prolonged period. The in vitro observed ideal drug release rates from anti-allergy agent-releasing drug delivery systems would thus approximate the release rates observed with antibiotic systems albeit on an extended time scale, with a rapid initial rise in concentration to reach therapeutic concentrations being more or less necessary depending on the severity of the allergic signs and symptoms, followed by a period of slower, sustained release to maintain drug tissue concentrations. Similar to antimicrobial therapy, it is unnecessary for these agents to be tapered and they can be discontinued quickly if needed. A summary of studies investigating the release of anti- In vivo: ketotifen concentration in tear film over 36 hours determined by HPLC
In vivo: 19.53 μg/ml of ketotifen detected in tear film while wearing loaded contact lenses after 24 hours, which is above effective concentration of 2 μg/ml Table 3 . Selected contact lens drug delivery experiments investigating delivery of anti-allergy agents
Contact lenses for ophthalmic drug delivery Hui allergy agents from contact lens materials is presented in Table 3 . Commercial contact lenses have been investigated for the uptake and release of the mast cell stabiliser cromolyn sodium and the combination drug ketotifen fumarate. 15, 59 Observed over 50 hours, lenses with the greatest water content (alphafilcon A) were demonstrated to release the greatest amount of cromolyn sodium into solution, although as is typical, this release rate was rapid and occurred primarily only during the very early phases of observation. 59 With ketotifen fumarate, the effects of surface charge influencing the release of the drug were observed with charged hydrogel (etafilcon A) and silicone hydrogel (balafilcon A) commercial contact lenses demonstrating some of the greatest release into solutions with 284.5 AE 29.8 μg/lens and 227.6 AE 14.7 μg/ lens being released over 24 hours, respectively. No lenses were able to sustain release for greater than four hours. 15 The effect of monomer composition in silicone hydrogel synthesis has also illustrated the effect of the hydrophobic and hydrophilic monomer ratio on ketotifen drug release. 66 Variation of the composition of the hydrophilic proportions of the hydrogel (DMA or N,Ndimethylacrylamide) to the hydrophobic components (TRIS) during synthesis results in variations to drug loading and drug release rate allowing for some ability of release tailoring depending on material composition. 66 In vivo, when lenses of different compositions were placed on to the ocular surface of rabbits, the most hydrophobic lenses demonstrate slowest release rates and longest mean retention time in the tear film (13.17 AE 1.92 hours) with clinically relevant tear concentrations still observable after 24 hours. 66 The histamine 1 (H 1 ) receptor is activated by histamine release from mast cells to create signs and symptoms of allergy on the ocular surface and in other parts of the body. 31 As the structure of this receptor is known, researchers have utilised this information to select different functional monomer combinations to best interact with antihistamine drugs such as ketotifen fumarate and olopatadine hydrochloride in molecularly imprinted polymer synthesis. 31, [67] [68] [69] [70] In these studies, functional monomers were selected based on side chain chemistry similar to the aspartic acid, lysine, arginine and tyrosine amino acids which form the docking site of the H 1 receptor. 67 Incorporation of multiple functional monomers similar to these amino acids such as acrylic acid, acrylamide, Nvinyl 2-pyrrolidinone and polyethylene glycol (200) dimethacrylate led to increasing affinity of the imprinted materials to ketotifen fumarate, with materials created with a combination of four different functional monomers demonstrating a six-to eightfold increase in ketotifen loading into the materials compared to ones which only incorporated a few. 67, 68 When examined in vitro under both infinite sink and microfluidic flow conditions, release was observed in three distinct phases under sink conditions over five days, and zero order or concentration-independent release was observed for 3.5 days under microfluidic flow rates. 69 In experiments with New Zealand White rabbits, imprinted materials with multiple functional monomers demonstrated therapeutically relevant ketotifen concentrations within the tear film for over 24 hours, with mean retention times of the drug in the tear film of 12.60 AE 0.37 hours compared to 3.36 AE 0.17 hours and 0.25 AE 0.07 hours for non-imprinted materials and eye-drops, respectively. 70 Olopatadine hydrochloride imprinted lenses have also been generated using similar methods using simultaneously multiple functional monomers such as acrylic acid, acrylamide, 2-acrylamido-2-methyl-1-propanesulfonic acid and benzylmathacrylate. 31 Through generation of multiple materials with different combinations of these selected functional monomers, the authors were able to demonstrate the effect of adding each of the selected functional monomers to the imprinting process with the ideal combination of monomers extending release to again more than 24 hours. 31 
Management of glaucoma with drug-delivering contact lenses
The modern medical management of glaucoma primarily consists of agents that lower the intraocular pressure (IOP) within the eye and work to either suppress aqueous production or increase aqueous outflow or some combination thereof. 8 As management of this disease is long term and requires daily pharmaceutical From a pharmacological perspective, the pharmacokinetic requirements for glaucoma treatment are relatively simple as they mainly involve the need to maintain constant therapeutic concentrations over time to ensure adequate IOP control. Maintenance of therapeutic levels indefinitely over time in a patient-friendly manner is thus most crucial rather than the speed at which these concentrations are achieved, and would be the primary requirement of any successful drug-releasing device over the time period through which it would be used. If observed in vitro, the release from the ideal glaucoma releasing device would have concentration-independent release kinetics, with the drug release rate sufficient to maintain effective drug concentrations at the site of action in the face of biological metabolism and excretion, without periods of under-or overdosage for as long as the device is being used. A summary of studies investigating the potential of contact lenses as a means to delivery anti-glaucoma medication is found in Table 4 , and a review on this specific topic has also been recently published.
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In vitro investigations of unmodified commercial contact lenses follow themes similar to those that have been observed with other drugs, with investigations into antiglaucoma medications such as timolol maleate demonstrating uncontrolled release in the order of minutes into solution. 59, 71 It is interesting to note that drug-soaked commercial contact lenses have been utilised experimentally in the management of IOP human subjects with IOP-related diseases. One of the earliest reports of the usage of drug-soaked contact lenses investigated the ability of pilocarpine-soaked Sauflon lenses in addition to oral acetazolamide to lower IOP over the course of two hours in patients with acute angle closure. 72 Similar IOP levels were found in the 25 experimental patients managed with this technique compared to a retrospective review of 25 patients managed with the 'intensive' 40 mg/ml pilocarpine eye-drop instillation protocol. 72 This study also provided some evidence of increased bioavailability as the contact lenses were loaded using only a 10 mg/ml pilocarpine solution, four times less than the concentration of the drops used in the typical management protocol. More recently, in a small case series of only three patients, researchers were able to demonstrate similar IOP levels in patients wearing timolol or brimonidine drugsoaked vasurfilcon A, etafilcon A or vifilcon contact lenses for 30 minutes a day as compared to daily eye-drop therapy. 71 The loading concentrations for the contact lenses were generated from a one in 10 dilution of the commercially available drops, again supporting the possibility of increased bioavailability simply through usage of the contact lens delivery system improving drug retention time.
Vitamin E modification of commercial contact lenses has demonstrated some success in affecting the release kinetics of the anti-glaucoma drugs timolol maleate and dorzolamide hydrochloride. [73] [74] [75] Modification of commercially available narafilcon A lenses with vitamin E coatings increased the drug release time in vitro more than 20-fold from four to 84 hours. 74 When these lenses were used for continuous wear for four days in a population of spontaneously glaucomatous beagle dogs compared to daily timolol eye-drop therapy or daily replacement of an unmodified drug-soaked narafilcon A lens, there were no statistically significant differences in IOP levels as measured by Tonopen. 74 Similar in vivo findings in glaucomatous dogs were observed when this technique was applied to lotrafilcon A lenses. 73 When these modified lenses were used with daily replacement, no difference in IOP was observed between vitamin E coated, unmodified lenses and eye-drop therapy, suggesting a similar dose was being delivered. 73 Crucially in this experiment, the IOP in the untreated eye was also monitored and a decrease was observed only in dogs who received eye-drop therapy, suggesting little or no systemic absorption of timolol when the contact lens delivery system was used. 73 The researchers have also investigated the ability of the barrier to modify release simultaneously of two anti-glaucoma drugs, timolol maleate and dorzolamide hydrochloride. 75 In vitro, vitamin E incorporation individually increased drug release times from 0.7 and 2.5 hours of release to 24.6 and 36 hours for timolol and dorzolamide, respectively, and this further increased to more than 40 hours when both drugs were simultaneously loaded into the lens. 75 The authors have speculated that there is some type of interaction occurring with both of these drugs within the materials as an explanation for this increase when both drugs are used together. 75 When used in vivo, again in glaucomatous beagle dogs, there were significant IOP lowering effects observed and the lowering of IOP persisted for up to seven days even after cessation of vitamin E lens wear therapy. 75 The authors speculate that this was due to the formation of drug depots within the ocular tissue. Unfortunately, continued IOP measurement after cessation of treatment was performed only after use of the simultaneous dual agent-releasing contact lenses so there is no data available on the persistence of IOP control when the dogs are treated with only a single agent-releasing contact lens or eye-drops.
One of the earliest examples of molecular imprinting being used as a technique to modify drug release from model contact lens materials was for the delivery of timolol maleate. 76 MAA was utilised as a functional monomer for the manufacture of pHEMA-and DMA-based hydrogel materials and it was observed that incorporation of MAA significantly increased the loading capacity of these gels. 76, 77 Incorporation of appropriate levels of MAA allowed for timolol release to be observed for over 24 hours. Application of these lenses in vivo in male Nippon rabbits demonstrated detectable tear concentrations for three hours, which was twice as long as that observed with non-imprinted lenses and three times as long as that seen with eyedrops alone. The researchers also elucidated key aspects such as the minimum cross-linker concentration of 80 mmol/L ethylene glycol dimethylacrylate necessary for the imprinting process to be observed successfully and the impact of pH on the swelling of gels impacting the amount of drug possibly loaded.
The prostaglandin analogues, including latanoprost, travaprost and bimatoprost, represent the current primary agents for the management of glaucoma due to their once a day dosing frequency and comparatively mild adverse effects. 8, 41 Latanoprost has been incorporated into PLGA films of various thicknesses (20 to 45 μm) and various ratios of glycolide to lactide, prior to being encapsulated between two layers of methafilcon contact lens material. The resultant PLGA-lens system is substantially Contact lenses for ophthalmic drug delivery Hui thinner than previous attempts at incorporating a drug-releasing PLGA film within a contact lens material seen with econazole and ciprofloxacin, although it is still not thin enough to be completely transparent, necessitating the removal of the central portion of the film which would overlay the pupil and allow for vision. [39] [40] [41] Thicker incorporated PLGA films (40-45 μm) were demonstrated to release latanoprost in vitro into solution for at least 28 days, with a relatively constant drug release rate of approximately 1 μg/day observed after an initial burst release period. When left on the surface of New Zealand White rabbits over the course of 28 days, these lenses were able to achieve a significantly higher maximum latanoprost concentration within the anterior chamber compared to conventional drop therapy, although to such a degree which could potentially be considered an overdose (1473 AE 892 ng/ml versus 54 AE 18 ng/ml with eye-drops). The observed average concentration of latanoprost during daily administration of eyedrops was 12.8 AE 3.4 ng/ml, which compares favourably to the average steady state concentration of between 5.6 AE 8.2 ng/ml and 39.6 AE 24.2 ng/ml between three and 28 days of lens wear with PLGA film lenses. 41 Presoaking of the highest releasing lenses in PBS for one day prior to insertion substantially decreases the observed maximum concentration within the aqueous humour to 74 AE 48 ng/ml although this also decreased the steady state concentration observed between days three and 28 of lens wear to 5.5 AE 2.4 ng/ml. The authors also report some evidence of contact lens overwear as some of the rabbits developed areas of corneal neovascularisation, although it should be noted that lenses were kept on the eye with the aid of a partial lateral tasorrhaphy throughout the course of 28 days of lens wear. 41 
CONCLUSIONS AND FUTURE DIRECTIONS
There has clearly been significant development and interest into contact lenses as an alternative means to deliver pharmaceutical agents to the eye and ultimately in the management of ocular diseases. Unmodified, commercially available contact lenses have been demonstrated to be able to release in vitro clinically relevant amounts of anti-infective, anti-inflammatory, anti-allergy and anti-glaucoma drugs albeit in an apparent uncontrolled fashion. The mere presence of a contact lens may improve bioavailability when worn in animals or in humans as evidenced by similar treatment effects even if lenses are loaded with substantially lower concentrations of solutions compared to administered eye-drops. Drug release kinetics can be modified through incorporation of surface-bound molecules such as nanoparticles or liposomes, or through deposition of diffusion barriers such as vitamin E. Generation of tailor-made drug-releasing materials can be through incorporation of functional monomers to specifically interact with molecules of interest to create molecular memory with the materials to slow down diffusion away from the materials in the final polymerised state, a process known as molecular imprinting, through the modification of the material ionicity, or through incorporation of a drug reservoir such as PLGA. The field continues to evolve and develop new in vitro methods to evaluate drug release to best mimic or perform predictions to the drug release kinetics observed when placed in vivo, with drug release experiments ranging from release within large volumes of buffered saline which are not replenished to microfluidic devices capable of passing through fluid volumes at rates similar to those seen on the ocular surface, although there still remains research necessary to properly develop and model in vivo drug kinetics in the laboratory. Application of these materials to animal or human models or in the management of active disease states has been done experimentally with some The next steps in the field are to begin to truly tailor the drug release characteristics of these materials to the necessary pharmacological requirements of the disease being treated, and to demonstrate measurable improvements in disease management or patient compliance. Proper selection of ocular disease and drug combination, and envisaging of how the drug delivery system will work in this context are thus crucial for eventual clinical implementation. The other challenge is to ensure that generated materials function as well as their contact lens namesake, with appropriate properties for vision and refractive error correction in a biocompatible manner. Other practical aspects will need to be investigated as these systems mature toward clinical practice, such as issues surrounding sterilisation, shelf life, and device insertion and removal. Device sterilisation and preservation against microbial contamination looms as an important regulatory hurdle to be overcome prior to device approval. Both the lens material and active pharmaceutical agent must remain viable throughout the sterilisation and packaging process to ensure an appropriate shelf life. This may limit the potential pool of material and drug combinations. The use of preservatives to prevent contamination may present its own challenge, as the lens itself is liable to take up and release these molecules, leading to undesirable doses of preservatives delivered to the ocular surface. Finally, insertion and removal of these devices merits its own discussion. For acute management, insertion and removal by the attending health-care practitioner is feasible, but for chronic management involvement of the patient becomes necessary. When considering that many chronic ocular diseases occur in the elderly where manual dexterity is an issue, strategies utilised by the rest of the contact lens industry to fit these particular populations into lenses successfully, such as continuous or overnight wear, will have to be investigated for their feasibility with these devices.
